R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential. The phase II program for treatment of... The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the...
- Mechanism
- Curator reviewed
R673 is a novel NK1 antagonist that penetrates the blood-brain barrier, has excellent safety and tolerability and shows low P450-based drug interaction potential. It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning of limbic system with respect to anxiety and depression.
- Primary indication
- Investigated for use/treatment in depression and anxiety.Curator reviewed
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with R673, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account